Samuel So

Clinical Focus

• Cancer> GI Oncology
• Gastrointestinal Cancers
• Gastrointestinal Cancers - Surgical Oncology
• General Surgery
• Liver Cancer

Administrative Appointments

• Committee on the Prevention and Control of Viral Hepatitis in the United States, Institute of Medicine of the National Academies (2008 - 2010)
• Roundtable on Health Disparity, Institute of Medicine of the National Academies (2008 - 2010)
• Board on Population Health and Public Health Practice, Institute of Medicine of the National Academies (2006 - 2009)
• Conflict of Interest Committee, Stanford University School of Medicine (2008 - 2010)
• Appointments and Promotion Committee, Stanford University School of Medicine (2007 - 2010)
View All 22administrative appointments of Samuel So

Honors and Awards

• Fervent Global Love of Lives Award, Chou-Ta Kuan Cultural and Education Foundation, Taiwan (2008)
• 10th Annual Salute to Excellence Award, American Liver Foundation (2008)
• 34th Annual Award, Chinese Hospital, San Francisco (2007)
• Star Award for Community Service, Asian Americans for Community Involvement, San Jose (2007)
• Best Doctors in America, Woodard/White Compendium (1998-present)

Professional Education

Postdoctoral Advisees

Kin Wai Sun , Song Wu

Graduate & Fellowship Program Affiliations

• Surgery

Community & International Work

• HBV Catch-up vaccination in China, China 
• Three-for-Life, San Francisco 
• Annual Youth Leadership Conference on API Health, Stanford University 
• Evaluate and Develop Strategies for HBV and Liver Cancer Prevention for the Philippines 

Web Site Links

• Asian Liver Center

Current Research Interests

Through a 3 pronged comprehensive program: translational and clinical research, early detection and treatment, and promoting education, awareness and immunization, we are working towards the development of new strategies that will lead to the elimination of hepatitis B worldwide and reduce the threat and incidence of liver cancer. Our current research efforts focus on evaluating potential new diagnostic and treatment markers and novel targeted therapy for primary liver cancer.

Clinical Trials

• Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma Recruiting
• PII Combination SBRT with TACE for Unresectable Hepatocellular Carcinoma Recruiting
• Microarray Analysis of Gene Expression in Liver Tumors Completed
• Phase III Study of PI-88 in Post-Resection Hepatocellular Carcinoma (PATHWAY) Terminated
• Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy Terminated

Publications

• Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China. Hutton DW, So SK, Brandeau ML. Hepatology. 2010; 51 (2): 405-14
• Eliminating the threat of chronic hepatitis B in the Asian and Pacific Islander community: a call to action. Chao SD, Chang ET, So SK. Asian Pac J Cancer Prev. 2009 Jul-Sep; 10 (3): 507-12
• Stopping a silent killer in the underserved asian and pacific islander community: a chronic hepatitis B and liver cancer prevention clinic by medical students. Lin SY, Chang ET, So SK. Asian Pac J Cancer Prev. 2009 Jul-Sep; 10 (3): 383-6
• 3 For Life: a model pilot program to prevent hepatitis B virus infection and liver cancer in Asian and Pacific Islander Americans. Chang ET, Sue E, Zola J, So SK. Am J Health Promot. 2009 Jan-Feb; 23 (3): 176-81
• The Jade Ribbon Campaign: a model program for community outreach and education to prevent liver cancer in Asian Americans. Chao SD, Chang ET, Le PV, Prapong W, Kiernan M, So SK. J Immigr Minor Health. 2009; 11 (4): 281-90